Editing AUA: Overactive Bladder (2019) (section)

==== Options ====

* '''<span style="color:#ff0000">Recommended</span>'''
** '''<span style="color:#ff0000">Oral anti-cholinergic</span>'''
** '''<span style="color:#ff0000">Oral β3-adrenoceptor agonists</span>'''
* '''<span style="color:#ff0000">May be offered</span>'''
** '''<span style="color:#ff0000">Transdermal oxybutynin (patch or gel)</span>'''
*'''Consider beginning with the lowest possible dose and titrate slowly while carefully assessing for the balance between symptom control and AEs.'''
**In older patients who may metabolize drugs differently, it is advisable to start with a minimal dose and titrate as tolerated.
**Optimizing medication tolerability is critical to obtaining patient compliance in the treatment of this chronic condition.
*Compliance with a once daily dosing is greater than with medications taken more than once a day.